Clinuvel Pharmaceuticals Limited (ASX: CUV)
Sector: Health Care
Market cap: A$365M (as of 2 Nov 2026)
Clinuvel Pharmaceuticals Ltd. is a leading and innovative Australian company focused on the development of SCENESSE (afamelanotide), its proprietary first-in-class drug, as a photoprotective in a range of UV and light related skin disorders a
Data as of 2 Nov 2026.
Substantial holders — latest moves
| Date | Holder | Move | Holding | Source |
|---|---|---|---|---|
| 24 Sept 2026 | Vanguard Group (The Vanguard Group, Inc. and its controlled entities) | Entry | ?% → 5.15% | Filing ↗ |
| 2 Sept 2026 | Vanguard Group (The Vanguard Group, Inc. and its controlled entities including Vanguard Investments Australia Ltd.) | Exit | ?% → 4.972% | Filing ↗ |
| 14 Aug 2026 | Vanguard Group (The Vanguard Group, Inc. and its controlled entities) | Entry | ?% → 5.003% | Filing ↗ |
| 26 Apr 2022 | A.C.N. 108 768 896 PTY LTD | Exit | — | Filing ↗ |
| 22 Dec 2020 | Clinuvel Pharmaceuticals Ltd (ACN 089 644 119) (Company), A.C.N. 108 768 896 Pty Ltd (ACN 108 768 896), Clinuvel (UK) Ltd, Clinuvel, Inc, Clinuvel AG, Clinuvel Singapore Pte Ltd, Vallaurix Pte Ltd, Clinuvel Europe Ltd, Vallaurix MC Sarl | Decrease | 9.24% → 5.93% | Filing ↗ |
Director trades — on-market
Cash and runway
| Metric | Value | As of | Source |
|---|---|---|---|
| Cash | A$141M | 31 Dec 2022 | Filing ↗ |
Latest cash figure is from 31 Dec 2022 and may predate a later quarterly filing.
Ask about CUV in Claude or ChatGPT
Add the Capital Signal connector at https://capitalsignal.io/api/mcp, then ask:
- Has CUV raised money in the last year, and at what discount?
- What was CUV's latest cash position and runway?
Loading CUV…